Journal of Drug Metabolism & Toxicology

Journal of Drug Metabolism & Toxicology
Open Access

ISSN: 2157-7609

+44 1285300058

Fei Li

Fei Li

Fei Li
Laboratory of Metabolism, National Cancer Institute, National Institutes of Health


Dr. Fei Li is currently working as Visiting Fellow, Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, USA.

Research Interest

Metabolism, toxicity, and carcinogenicity of drugs and chemicals: Cytochromes P450 (P450) involve in metabolism of drugs and chemicals in vivo, and catalyze the inactivation or metabolic-activation of chemical carcinogens. A multi-faceted approach, including mouse model, molecular biology, and analytical chemistry is used to investigate the roles of metabolism enzymes in toxicity and
carcinogenicity. I have focused on the study of the toxicity of several drugs, including ifosfamide, cyclophophamide, thioTEPA, and procainamide, and the effect of CYP1B1 on benzo[α]pyrene using CYP1B1-null and humanized mice. Part of results has been published on Biochemical Pharmacology and British Journal of Pharmacology.
• Metabolic profiling of drug efficacy and toxicity: Xenobiotic receptors, such as peroxisome proliferator activated receptor (PPAR) and farnesoid X receptor (FXR), can mediate the metabolic response of organism to the chemical environment. However, in many cases, activation of xenobiotic receptors can
lead to toxic and carcinogenic responses. The transgenic mice, including knockout and humanized mice, can be used to study the mechanism of drug efficacy and toxicity. I have worked on the effect of
PPARα and FXR on drug efficacy and toxicity. Part of results has been published in Journal of Lipid Research and Journal of Proteome Research.
• Identification of biomarkers for diseases using mass spectrometry based-metabolomics: Metabolomics using liquid and gas chromatography linked to mass spectrometers (UPLC-QTOFMS and GC-MS) as analytical platforms, is being actively used to systematically identify and quantify all metabolites in a
given organism or biological sample. The small molecule biomarkers of diseases are identified through the targeted- and untargeted-metabolomic analysis of metabolites in serum, urine and tissue homogenate. Some endogenous biomarkers of several diseases, including cancer, diabetes, liver cholestasis, and glaucoma, have been identified in my research using this technology. Part of results has been published in Journal of Biological Chemistry.